| Names | |
|---|---|
| Preferred IUPAC name | Pyridine-3-carboxamide |
| Other names | Niacinamide Nicotinic acid amide Nicotylamide |
| Pronunciation | /naɪˌkəʊ.tɪˈnæm.aɪd/ |
| Identifiers | |
| CAS Number | 98-92-0 |
| Beilstein Reference | 232810 |
| ChEBI | CHEBI:18075 |
| ChEMBL | CHEMBL95 |
| ChemSpider | 1037 |
| DrugBank | DB02701 |
| ECHA InfoCard | 100.027.007 |
| EC Number | EC 3.5.1.19 |
| Gmelin Reference | 6042 |
| KEGG | C00153 |
| MeSH | D017382 |
| PubChem CID | 938 |
| RTECS number | QS3675000 |
| UNII | 5NI0VZ4UCV |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | urn:epatox:4939 |
| Properties | |
| Chemical formula | C6H6N2O |
| Molar mass | 122.12 g/mol |
| Appearance | White crystalline powder |
| Odor | Odorless |
| Density | 1.40 g/cm3 |
| Solubility in water | freely soluble |
| log P | -0.37 |
| Vapor pressure | <1 mm Hg (25 °C) |
| Acidity (pKa) | 14.2 |
| Basicity (pKb) | 6.93 |
| Magnetic susceptibility (χ) | -51.0e-6 cm³/mol |
| Refractive index (nD) | 1.588 |
| Viscosity | Viscous liquid |
| Dipole moment | 4.15 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 160.2 J·K⁻¹·mol⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | –156.7 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -3888 kJ·mol⁻¹ |
| Pharmacology | |
| ATC code | A11HA01 |
| Hazards | |
| Main hazards | May cause eye, skin, and respiratory tract irritation. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | GHS07 |
| Signal word | Warning |
| Hazard statements | H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | Precautionary statements: "P264; P270; P305+P351+P338; P337+P313 |
| Flash point | 129 °C |
| Autoignition temperature | 455 °C |
| Lethal dose or concentration | LD50 (oral, rat): 3,500 mg/kg |
| LD50 (median dose) | LD50 (median dose): 5 g/kg (rat, oral) |
| NIOSH | RN=98-92-0 |
| PEL (Permissible) | Not established |
| REL (Recommended) | 500 mg/day |
| IDLH (Immediate danger) | Not listed. |
| Related compounds | |
| Related compounds | Nicotinic acid Nicotinamide riboside Nicotinamide adenine dinucleotide (NAD+) Nicotinamide mononucleotide (NMN) Nicotinamide riboside chloride 1-Methylnicotinamide |
| Property | Manufacturer’s Technical Commentary |
|---|---|
| Product Name | Nicotinamide |
| IUPAC Name | 3-pyridinecarboxamide |
| Chemical Formula | C6H6N2O |
| Synonyms & Trade Names |
|
| HS Code & Customs Classification |
HS Code: 293629 Customs classification of nicotinamide falls under organic chemicals, specifically other vitamins and their derivatives. Grade-based segmentation often determines whether additional certification or region-specific documentation is needed at customs. For shipments to nutraceutical or pharmaceutical destinations, batch traceability, impurity profiling, and GMP status may require supporting documentation at clearance. Material sourced for animal feed, food fortification, or industrial intermediates sometimes aligns to subcategories within 2936 at the country level, reflecting the intended end use and local regulatory requirements. |
In our production experience, nicotinamide presents most commonly as a white crystalline powder, with minimal odor. The bulk product’s color and form vary by synthesis route, purity target, and point of final isolation. Off-white or yellowish tinges may indicate trace organic impurities or degradation byproducts, particularly in batches held under suboptimal storage. Melting point readings shift in correlation with both water content and impurity profile, so routine differential scanning calorimetry checks are important for grade assurance. Boiling point and flash point do not have practical significance in bulk handling, since the material typically decomposes before boiling under ambient pressure.
Nicotinamide’s core structure resists moderate heat and neutral aqueous conditions. Alkaline environments, oxidizers, and prolonged UV exposure promote degradation or discoloration, generating both in-spec and off-spec impurities. Degradation rates are trackable by high performance liquid chromatography. For customers formulating solutions, pH adjustment within buffered ranges helps maintain active compound levels over time. Bulk handling requires monitoring of cross-contamination with strong acids, bases, or reducing agents to avoid exothermic side reactions.
Solubility varies significantly with temperature and solvent polarity. In typical operations, deionized water and lower alcohols readily dissolve the material; the final solution clarity depends on both grade and filtration of insoluble fines. Solution preparation for downstream use (e.g., pharma, feed, cosmetics) benefits from gentle agitation and controlled pH. Process residues or non-dissolved particles must be removed for applications demanding low turbidity, supported by microfiltration steps validated in-process.
Detailed specifications, including assay and impurity thresholds, are defined by grade: pharmaceutical, food, or industrial. Pharmaceutical grades target minimal residual solvents and specified heavy metal limits, enforced through validated compendial or customer-agreed methods. Food and feed grades carry more flexible but traceable impurity profiles. The final grade is determined by the product’s analytical release panel and intended end-use sector.
Impurities stem from both starting material quality and process route. Key contributors include unreacted intermediates, catalyst residues, or oxidation byproducts. Batch impurities are profiled by HPLC and spectroscopic methods. Exact limits are grade- and region-specific, often referencing pharmacopeial or food additive regulations for international shipments. The risk of nitrosamine formation receives special focus, with preventive controls at both process and supply chain levels.
Test procedures reference pharmacopeial monographs, AOAC, or in-house analytical methods depending on grade. Assays of active content use UV spectrophotometry or HPLC calibrated with certified reference standards. Moisture, residue on ignition, and microbiological status receive batch-level controls if required by application sector. Each release includes verification against internal and external compliance benchmarks.
The process begins with chemical-grade 3-cyanopyridine or related pyridine derivatives as core raw materials. Feedstock selection is based on both purity and supplier traceability, with routine physical-chemical incoming goods testing. Sourcing strategy balances price, consistency, and regulatory acceptability for export-driven supply chains.
The synthesis most often employs catalytic hydration of 3-cyanopyridine, with process variants using either gas-phase or aqueous-phase reactors. The route is chosen to fit scale, impurity control, and waste minimization targets. Reaction monitoring relies on online sampling and gas analysis to suppress unwanted byproduct formation.
Continuous and batch modes are both practiced depending on the target market. Post-reaction, the crude product is purified by crystallization from aqueous media and multi-step filtration. Control points focus on temperature, solvent recovery, and pH, since both yield and final impurity level depend tightly on these variables. Process deviations often appear as color shifts or increased insoluble fines, triggering corrective actions in downstream purification.
Each lot undergoes a predefined QC protocol: identity by IR/NMR, residual solvents by GC, and impurity screening by HPLC. Release standards build on both customer and regulatory input, documented by Certificates of Analysis for each batch. Product is withheld from shipment pending completion of full analytical review.
Nicotinamide’s amide group permits both hydrolysis to nicotinic acid and derivatization toward esters or salts under controlled catalysis. Its aromatic ring undergoes standard electrophilic and nucleophilic substitutions when processed with suitable reagents.
Process intensification efforts have focused on using selective metal or enzymatic catalysts for hydration stages. Reaction temperatures are generally moderate, restricted by product thermal sensitivity and impurity avoidance; solvent choice shifts process yield and side-product profile. Downstream modifications—such as formation of N-alkyl or acyl derivatives—require anhydrous, inert, or buffered systems depending on operational scale and desired derivative.
Key derivatives include nicotinamide salts, esters, and complexes for specialized markets. Synthesis of these follows controlled neutralization, acylation, or condensation protocols. Each derivative’s process route depends on customer application, targeted impurity maximums, and regulatory pathways for the destination end-use sector.
Store product below target temperature and away from elevated humidity. Container closure systems require compatibility testing to prevent ingress of moisture or volatile organic compounds. Direct light exposure increases risk of slow degradation or color change; nitrogen blanketing is optional but recommended for high-purity stock inventory.
Standard practice employs high-density polyethylene or glass containers with validated liner compatibility. Certain applications may demand dedicated anti-static or UV-resistant vessels.
Practical shelf life depends on grade, end-use requirements, and container integrity. Degradation is signaled by yellowing, odor change, or reduced assay. Each of these triggers re-testing or batch segregation for non-conforming material.
Nicotinamide holds a low hazard profile under most regulatory frameworks, but dust formation requires workplace exposure management. Respiratory and eye irritation are primary risks if excessive airborne particles build up in plant environments, addressed by local exhaust and PPE. Current GHS classification, hazard statement, and precautionary advice align with regional regulatory updates and inventory listings.
Acute toxicity benchmarks reference established toxicological literature for oral, dermal, and inhalational routes. Exposure limits for occupational settings depend on total dust load; continuous air quality monitoring systems supplement procedural controls. Handling best practices focus on minimizing dust generation, using sealed transfer lines, and training operators in correct spill and exposure response.
As an established manufacturer with vertically integrated supply chains for nicotinamide, we scale production using multiple synthesis lines aligned with pharmaceutical and food-grade regulatory standards. Annual output varies depending on shutdown schedules for maintenance, regulatory audits, or plant debottlenecking, with capacity prioritization for long-term contract customers. Actual supply lead times are directly affected by upstream raw material sourcing, energy supply consistency, and periodic compliance inspections. Peak demand periods in export markets call for advanced allocation planning; unpredictable demand spikes can impact spot availability.
Typical lead times for standard grades are influenced by current plant load and logistics coordination, normally quoted based on ex-works or FOB terms. MOQ depends on batch process economics, grade-specific demand, packaging preference, and customer qualification status. Custom-ordered grades or enhanced purity batches will reflect longer lead times and higher MOQs due to extended final testing, documentation, or segregation requirements.
Commercial shipments are delivered in package types selected for product grade and transit risk: food or pharma grade often ships in fiber drums with PE liners or high-barrier bags, while technical grade supplies utilize bulk bags or HDPE drums. Tamper-evident seal integrity is essential for high-value grades, particularly where customer audits stipulate traceability and secondary containment. Packaging alteration for customer-owned containers or special markings requires pre-approval and may affect batch scheduling.
Shipping modes—sea, land, or air—depend on regional regulatory acceptance, shelf-life in transit, and total weight per consignment. Payment terms reflect credit risk analysis, order frequency, and customer compliance history. Major accounts may be extended deferred payment, whereas new or high-risk regions transact on advance or irrevocable LC basis. Export documentation is custom-prepared for destination compliance, impacting dispatch cycle time.
Nicotinamide production cost hinges on both the purity and source of beta-picoline or related precursors, which are subject to petrochemical market swings, catalyst supply constraints, and process yield factors. Catalysts and solvents do not remain constant in cost or performance; process route optimization can shift cost balance depending on prevailing market quotations. Transport, waste neutralization, and regulatory surcharges form a non-trivial part of landed cost.
Raw material pricing volatility stems from global supply shocks—energy price hikes, plant incidents, environmental shutdowns, or export restrictions on primary chemicals. Increased environmental regulation in major production hubs (especially CN, IN) can sharply curtail upstream supply or introduce emission fees, translating directly into delivered cost shifts. On the demand side, regulatory reclassification or sudden adoption in high-volume nutraceutical programs may drive accelerated price movement.
The core determinants of price difference arise from product grade classification. Food, pharma, or injectable-grade nicotinamide incur both higher process and release testing outlay, including validated trace impurity quantification (e.g., nitrosamine levels, heavy metals), whereas feed or industrial grades follow less stringent documentation. Regulatory-driven customer audits and international certification (e.g., USP, JP, EP) increase release cost per unit and enforce traceability to validated batch records. Certified halal, kosher, or allergen-free batches also carry inspection and segregation surcharges. Custom packaging, additional QA sampling, or additive-free processing generate further tiered pricing.
Global demand is distributed across key economies with distinct regulatory, consumption, and supply chain profiles. Significant volumes are targeted for vitamin formulations, API synthesis, animal nutrition, and cosmetics, often regulated differently across exporting and importing regions. Upswings in wellness and supplement categories (notably in US/EU) escalate off-take rates, while feed premix demand fluctuates in IN/CN based on agricultural cycles. Supply chain disruptions—especially following enacted environment-driven plant closures in CN or distribution bottlenecks at global ports—tend to tighten available spot cargo and raise contract price floors.
US and EU buyers demand pharmaceutical or food grade with rigorous QA and chain-of-custody documentation. These regions regularly respond to regulatory cues, such as USP or REACH changes, by shifting volume among certified suppliers. Japan parallels EU on documentation, though batch size preference is smaller and contractual auditing is frequent. India and China dominate as both manufacturing bases and large-volume consumer markets, periodically impacted by government policy on chemical effluent treatment and VAT systems. Import dependency exacerbates price spikes in regions lacking upstream chemical infrastructure or holding lower domestic output.
Looking forward to 2026, base-case industry consensus shows moderate upward pricing pressure. This trajectory reflects mounting compliance costs linked to environmental policies in East Asia, investments into process automation for pharmaceutical traceability, and intensifying demand from nutraceutical and animal nutrition sectors. Short-term market shocks—in particular, supply-side regulatory actions or large-scale production incidents—could introduce price surges, but stability is favored where multi-sourcing and established contract allocations are maintained. Grade differentiation and certification margins are expected to widen as downstream sectors face stricter purity and traceability standards.
Market views draw on internal tracking of procurement costs and sales allocation, public customs data for actual export/import trends, and industry benchmarking of audit and compliance expenditures. Data aggregation reflects verified transaction histories, field experience with periodic price resets, and comparison against global logistics trends. Production and capacity statements are based on operational records, not quoted nameplate capacity.
Recent consolidation among upstream chemical producers and revisions to national API standards in key export markets have had a marked effect on grade segregation and batch release pipeline. Several regulatory-driven shutdowns in China for environmental compliance reduced short-term output and forced volume reallocation to certified lines.
Updates to USP and European Pharmacopoeia monographs now emphasize trace nitrosamine control, with new detection limits requiring validated in-process and post-release testing protocols. The US FDA and EU authorities continue to intensify inspections for data integrity and raw material traceability, raising qualification and documentation standards for all pharmaceutical-grade exports.
To mitigate regulatory and price volatility risk, production lines are being upgraded with additional containment for impurity management and more robust batch genealogy systems. Supply chain teams are broadening global sourcing for primary inputs and investing in local warehousing capacity to smooth out lead time variation. Participation in third-party certification programs and pre-shipment inspection regimes reflect a manufacturer commitment to downstream compliance and customer audit readiness.
In our facility, nicotinamide finds regular use in nutritional products, pharmaceutical formulations, personal care bases, animal feed, and electroplating solutions. Applications in multivitamin blends and skin care call for food or pharma-grade material. Technical and feed industries prioritize cost-structure and impurity thresholds suited to their downstream processes.
| Industry | Typical Grade | Key Quality Demands |
|---|---|---|
| Pharmaceutical | USP/EP/BP/JP | Low volatile organics, tight limits on heavy metals, validated traceability |
| Food & Beverage | FCC/Food Grade | Compliance with food contact standards, low-level residual solvents, strict contaminant screening |
| Cosmetics | Cosmetic Grade/Pharma Grade | Fine particle control, skin compatibility, allergen screening (grade-specific) |
| Animal Nutrition | Feed Grade | Economic value, batch consistency, tolerance to wider impurity ranges (within regulatory standards) |
| Industrial (Electroplating/Chemical Synthesis) | Technical Grade | Primary concern is cost-balance to required process performance; impurity profile aligns with allowable process impact |
Grade selection links directly to regulatory and downstream processing needs. For pharma and food, particle size control, solvent residue levels, and trace contaminants receive the most scrutiny in quality control. Cosmetic lines rely on narrowed allergen and heavy metal screening. Technical grade prioritizes batch-operational consistency and specific impurity tolerance, which can vary by process.
Polymorph profiles and particle distribution can differ by synthesis route and post-processing steps. Hygroscopicity varies by grade, which will affect long-term storage and handling, especially in bulk packaging environments or high-humidity climates. Antioxidant activity, crucial in some food and cosmetic applications, is controlled by primary ingredient management and contaminant minimization via validated purification schemes.
Before requesting a quotation, application clarity saves iteration cycles. Raw ingredient used in a regulated dietary supplement or direct tablet manufacture falls under stricter audit and regulatory requirements compared to a bulk feed blend or specialty plating process. Pharmaceutical developers often require material with documentation from ICH Q7 GMP batches, while food and beverage firms focus on allergen controls and migration studies.
Reference to pharmacopoeial, food additive, or regional animal feed additive standards will drive permissible impurity thresholds and documentation level (DMFs, ingredient statements, declarations of GMP or HACCP). Inconsistent documentation or unclear batch origin disrupts formula registration and slows product launches downstream.
High-purity grades carry added tests for volatile organics, heavy metals, and trace intermediates. Cosmetic customers often require extra certification for contaminants listed by the country’s health authorities. Technical grade may tolerate greater impurity variation but requests for tighter specs increase cost. Discussing intended downstream processing and possible purification steps helps to avoid both over- and under-specifying quality parameters up front.
Adjustment of grade by batch size can influence supply reliability and inventory costs. Drug and nutraceutical manufacturers favor validated long-term supply agreements, often with multi-ton forecasts and lot tracking. Feed and technical users typically purchase by large bags or bulk, prioritizing economics and availability, and accepting wider variation within regulatory controls.
On-site trials and laboratory validation enable direct assessment of grade fit. Actual plant or lab data gives the proper context for appearance, solubility, flowability, compatibility, and reactivity with formulation excipients. Trial data can uncover unexpected issues linked to particle morphology, moisture uptake, or blending dynamics that rarely appear on standard product sheets.
Agricultural, petrochemical, or synthetic sources each bring distinct impurity footprints that show up in both regular testing and special investigations. Our trials have demonstrated that upstream solvent selections and intermediates dictate the spectrum of trace organics residual in final batches, with pharma and food routes requiring higher-purity inputs.
Choice of ammonolysis, catalytic hydrogenation, or alternative synthesis routes depends on intended market grade and overall impurity profile. Pharma-focused lines employ multi-step, closed systems with in-line monitoring while technical grades streamline process steps to reduce total cost, accepting broader side-product ranges.
In-process chromatography and controlled crystallization cycles serve as primary levers for impurity exclusion. Direct monitoring at these stages measures the effectiveness of heavy metal removal and controls for potential byproduct drift between batches.
Elevated reaction temperatures and prolonged solvent contact act as major contributors to breakdown and side reactions. We see variations tied to incoming raw batch quality, especially when the supply is interrupted or feedstock origin shifts. Contamination events trace back to start-up, shut-down transients or cross-batch mixing in multi-purpose plants.
Crystallization, activated carbon treatment, and phase separation feature as the principal cleanup steps. Choice of purge solvents, filtration media, and drying conditions targets grade-specific contaminant removal and moisture stabilization. The rigor of each step determines whether output passes for pharma, food, or feed applications.
Batch monitoring integrates HPLC purity tracking, particle size distribution, and moisture control to avoid out-of-spec batches. For pharma lines, we screen additional parameters such as endotoxin and microbial contamination. Technical grade processing accepts leaner control protocols, maintaining only those checks relevant to end-user process tolerance.
Consistency programs hinge on raw material traceability, repeated validation of control parameters, and tracking any recipe or operator change. Data trending at release flags gradual process drift long before significant quality deviation occurs.
Final release follows application and customer requirement–driven checklists that emphasize residue levels, contaminants, particle size, and appearance for premium grades. End-use-driven exceptions can be negotiated based on the process realities and post-processing in the customer’s facility.
Our approach to quality management focuses on both process validation and critical parameter control through every manufacturing stage. For pharmaceutical and food-grade nicotinamide, production sites operate under GMP-compliant frameworks, supported by ISO 9001 quality systems. The presence of ISO 14001 and ISO 45001 reflects ongoing commitments to environmental and occupational safety management, each independently audited and regularly reviewed after process changes or expansions. These certifications matter for customers who must document risk controls or supplier qualification to regulatory agencies.
Nicotinamide batches intended for regulated markets align with grade-specific standards, such as EP, USP, or FCC, according to the destination and downstream use. Kosher, Halal, and allergen-free declarations are issued based on adherence to verified raw material segregation and production line cleaning protocols. Manufacturers develop and update these certifications in response to regulatory reviews, raw material changes, or customer-specific audit feedback; export documentation reflects the current compliance status per lot and supply chain transparency practices.
Each production lot carries release documentation detailing analytical results, methods, and instrument calibration records. Certificates of Analysis provide test data according to the contract specification and reference the current pharmacopoeial monographs where applicable. Additional documents, such as TSE/BSE statements, residual solvent reports, and heavy metal analyses, are available upon request or per order. Regular customer audits and sample inspection programs drive continuous improvement in documentation accuracy and transparency. Technical dossiers and regulatory support files are maintained in preparation for registration dossiers or responses to authority inquiries.
The reliability of supply for nicotinamide depends on continuous raw material qualification and proactive line maintenance. Large-scale reactors and crystallization units are reserved for contract volumes under long-term agreements. Production lots are released only after in-process and post-process checks, and volume commitments for key customers are safeguarded by backup capacity or inventory buffering. For urgent orders or campaign production, business terms are modified based on risk, current operations schedule, and market constraints.
Sourcing logic targets primary intermediates from established partners with verified analytical records and supply resilience. Shift-based production schedules flex in response to demand forecasts and global logistics constraints. Every lot release involves a review by technical and quality departments to assess batch records, impurity profiles, and deviation handling. Consistency plans adjust to reflect customer-required lead times, shelf-life sensitivity, and storage mode. Contingency plans address both planned maintenance and unplanned shutdowns, with finished goods warehousing adjusted according to annual capacity utilization and projected demand.
Sample requests are processed using dedicated pilot-scale reactors and isolated filling lines to avoid cross-contamination risks. The technical department reviews usage intent (formulation development, process validation, or regulatory filing) as the basis for sample lot selection. These test lots are inspected against a reduced panel of analytical standards unless the customer or regulatory body requests full release data. Documentation accompanying samples can be extended to cover stability data, origin traceability, and atypical impurity investigations if warranted by novel applications or new geographies.
Cooperation modes are shaped by customer inventory strategies and regional regulatory differences. Both spot and scheduled order fulfillment can be arranged, depending on forecast visibility and downstream project timelines. Long-term supply agreements may include renewal options, dual-sourcing backup, or clause-based price adjustments triggered by market or feedstock volatility. The technical team engages directly with downstream R&D or production staff to address formulation challenges, root cause investigations, or changes in compliance requirements. This approach supports efficient issue resolution, a reduction in lead time risks, and ongoing improvement in order certainty.
R&D for nicotinamide focuses on process efficiency, impurity control, and functional performance in end applications. Producers pay close attention to feedstock quality, especially in ammonia and 3-cyanopyridine sourcing, since raw material variability directly impacts downstream purity and yield. Manufacturers have invested in online analytical techniques to track reaction completeness and byproduct profiles in real time. Solid-liquid separation steps, such as crystallization control, rank as a routine optimization area for both pharmaceutical and food additive grades; fine-tuning temperature and solvent ratios narrows particle size range and minimizes batch-to-batch drift.
Demand for nicotinamide as a feed additive in aquaculture and pet care, along with its use in skin and nutrition formulations, continues to expand. Recent attention has gone toward functionalized derivatives and encapsulated forms targeting controlled release in dietary supplements. In personal care, formulators seek micronized or low-residual-metal grades that support growing regulatory and branding requirements. Processes are being adjusted to accommodate food-contact compliance limits for nitrosamines and other trace contaminants. Applications in agriculture and animal health have prompted re-evaluation of dusting, flowability, and slow-release formats.
One persistent technical hurdle in nicotinamide production relates to the byproducts and co-crystallization of isonicotinamide and residual starting materials. Upstream control of oxidation and nitrile hydration steps remains critical. Manufacturers implement multiple internal tests across synthesis to confirm low formation of process-specific contaminants, applying both batch and continuous process logic depending on facility layout. Recent process breakthroughs include catalytic upgrades that enable lower-temperature reactions and advanced filtration systems that support lower impurity carryover, reducing downstream rework rates. Formulation R&D has produced excipient blends optimizing dispersibility and reducing risk of caking in bulk storage.
Market growth is influenced by expansion in nutritional, pharmaceutical, and cosmetic industries. Regional regulatory updates drive differentiated demand for specialty grades, such as low-residual-solvent and allergen-free forms. As health trends in emerging markets accelerate, demand for tailored particle sizes and purity specifications is expected to increase. Manufacturers are updating capacity strategies and contingency raw material sourcing in response to evolving global trade and regulatory shifts.
Continuous production lines and digital process control are replacing batch-based systems in major nicotinamide facilities. Inline NIR and HPLC methods speed up impurity profiling, reducing batch Holds and supporting real-time release for food and pharma grades. Sustainable co-product management is under evaluation, with efforts underway to valorize side streams instead of incineration. Production sites are revisiting utility integration to cut steam and cooling demand specific to reaction and crystallization steps, which directly impact per-kilogram environmental load.
Green chemistry remains a R&D staple. Facilities are phasing in less hazardous solvents and greener nitrile hydration routes to reduce secondary emissions and worker exposure risks. New catalysts and water recycling strategies are tested in pilot campaigns targeting a reduction in wastewater volume and organic load concentrations. The focus tracks both compliance and customer chain-of-custody requirements, with expanded adoption of life cycle assessment metrics.
We maintain technical support desks staffed by experienced manufacturing and formulation chemists. Customers can access expertise on grade selection, regulatory compatibility, and process adaptation for different application sectors. Advisories are frequently issued for process modifications, particularly in response to changing formula regulations, raw material sourcing, or observed off-spec events in customer plants.
Application labs collaborate directly with customers to address technical bottlenecks. Areas of support range from refining particle size distribution and dusting control methods to process simulation for new food supplement blends. Our staff routinely assists with wet-milling, mixing, and tablet-press process troubleshooting. Tailored support involves evaluating end use requirements and providing real-world samples, pilot scale support, and continuous feedback until the target outcome aligns with customer’s technical benchmarks.
Production batches undergo release based on a combination of internal quality criteria and customer-defined standards. Any technical complaint registers an investigation that includes retained sample review, deviation analysis, and support for corrective strategies at the customer’s process site. Traceability for each lot is managed through integrated batch tracking systems, covering both raw material provenance and full finished product test records. Customers with recurring quality requirements receive regular process summary dossiers detailing key process adjustments, impurity trends, and risk mitigation status.
As a manufacturer that has managed nicotinamide production from raw material sourcing through final quality inspection, I see this compound not as a commodity, but as a foundation for many critical processes in industries worldwide. Our plant runs dedicated synthesis lines for nicotinamide, applying controlled conditions and validated process parameters. Every batch leaves our site only after passing multi-stage analysis, including HPLC, moisture content, and impurity profiling, aligned with industrial-grade requirements.
Our primary focus covers the pharmaceutical sector, with customers formulating tablets, injectables, and nutritional supplements. Food and feed manufacturers rely on our output for fortification and nutrition enhancement in processed goods. Cosmetic labs use nicotinamide for skin health formulations, and specialty chemicals producers use it for intermediates and fine chemicals. The scale we operate allows us to support both bulk industrial operations and smaller specialty runs, always using the same process discipline for each lot.
Every kilogram of nicotinamide originates from standardized synthesis and isolation procedures. There are no shortcuts in process control: temperature, pH, and feedstock purity stay under constant monitoring by experienced process engineers. Analytical staff review batch certificates before any shipment. Over years of operation, we have invested in automation and staff training to keep batch-to-batch deviation narrow, a factor recognized by clients in regulated industries. Changes to processes or raw materials follow documented change controls and impact assessments, reducing operational risk for downstream users.
For industrial and commercial customers, packaging reliability matters as much as chemical quality. Our dedicated packaging lines fill and seal nicotinamide in several commercially accepted formats, from fiber drums with PE liners to custom-designed tonnage sacks. These measures protect the product in transit and support automated material handling at the customer site. We maintain stocks in climate-controlled warehouses, reducing lead time for regular and project orders. Bulk and containerized shipment capability supports international buyers requiring scale.
Process changes, formulation development, or regulatory requalification efforts often lead buyers to request documentation or technical input. In practice, our technical staff interface directly with industrial customers for product data, regulatory compliance documentation, and application troubleshooting. Joint problem-solving at the formulation or process level has enabled several industrial clients to reduce downtime and improve product yield. We keep technical and analytical documentation current and review compliance with evolving standards such as pharmacopeial updates or food safety rules.
Direct access to the manufacturing process streamlines procurement. Buyers secure predictable timelines, cost transparency, and real-time updates on batch status. Manufacturers and distributors reduce risk, as the traceability and production history remain documented at source. For procurement teams, visibility into plant scheduling, raw material stocks, and available production windows helps meet planning targets. Commercial buyers gain from clear specification control, reliable supply, and immediate technical dialogue, supporting compliance and product innovation goals.
| Feature | Industrial Benefit |
|---|---|
| Validated Synthesis Process | Batch integrity and process repeatability for regulated uses |
| On-site Analytical Lab | Release testing and tailored documentation for audits |
| Commercial Scale Packaging | Optimized logistics, reduced contamination, improved safety |
| Technical Team Support | Solutions for application development and regulatory compliance |
| Inventory Management | Consistent lead times and reliable supply for production planning |
For any industrial buyer, product consistency, supply certainty, and technical clarity remain top priorities. Our approach as a direct producer keeps these aspects within our control—supporting manufacturers and commercial buyers facing complex sourcing and compliance landscapes.
In pharmaceutical manufacturing, every detail behind a raw material's specification traces back to production, analytical controls, and regulatory demands. Nicotinamide is no exception. As a manufacturer, we produce pharmaceutical-grade Nicotinamide to support strict requirements, not just for compliance, but for consistency and patient safety. Our perspective on purity and assay comes out of years of practical manufacturing and direct engagement with pharmaceutical clients and regulatory audits.
Pharmaceutical-grade Nicotinamide must conform to internationally recognized monographs, such as those set out in the United States Pharmacopeia (USP) and European Pharmacopeia (Ph. Eur.). These authorities define the minimum acceptable assay—expressed as a percentage of Nicotinamide per dry basis—as well as maximum allowable impurities to prevent health risks associated with residual solvents and contaminants. In our manufacturing lines, assay values for Nicotinamide typically land in the 99.0% to 101.0% range, calculated on a dried basis, as dictated by major pharmacopeias. We design our batch release criteria to favor the upper half of this range, offering reassurance to our customers who require rigorous input for their finished pharmaceuticals.
Pesticide residues, heavy metals, and potentially genotoxic impurities carry strict limitations in active pharmaceutical ingredients. We analyze every batch according to detailed specifications, using validated high-performance liquid chromatography (HPLC), mass spectrometry, and loss-on-drying for moisture control. Transparent QC records follow every lot—no batch ships without complete traceability and laboratory release. Our in-house analytical chemists operate calibrated equipment, audited regularly, to match each published pharmacopeia’s requirements. Clients often request additional impurity profiling to support regulatory submissions, and our technical team can provide this upon request.
From our standpoint as a factory, the distinction between assay and purity shapes every technical discussion. Assay measures the active content, calculated on anhydrous basis; purity relates more broadly to the absence of process or degradation-related material. Drug manufacturers need accuracy in active content—too little or too much shifts the finished dose, leading to problems in both low and high content uniformity testing. Purity limits ensure no unexpected or harmful substances interfere downstream. We structure our control documentation to differentiate both, list relevant test methods, and cross-reference international quality standards.
It takes controlled raw material sourcing, validated process steps, and stringent final drying conditions to sustain these purity standards batch after batch. From initial charging of the reactor to final drum filling, each manufacturing run undergoes online sampling and in-process controls. Moisture content receives particular attention; too much moisture may reduce the active assay and promote degradation, so we run real-time Karl Fischer titrations prior to drum sealing.
Documented analytical methods, traceable lab results, and repeatable purity ensure safe use and regulatory acceptance worldwide. Our customers—ranging from generic manufacturers to multinational pharma firms—request detailed batch documentation and supply chain transparency. We integrate each specification into our ERP and quality systems, giving clients peace of mind during audits and regulatory submissions. When requests arise for stricter impurity thresholds or test parameters, our technical support team reviews the requirement and can adjust internal controls to meet market-specific or client-specific needs where technically feasible.
As the direct manufacturer, we recognize the importance of traceability, technical support, and clear communication when it comes to documentation and test methods. Pharmaceutical projects rely on every kilogram of Nicotinamide meeting the published assay and purity every time. Our production, testing, and release protocols arise from that central responsibility—ensuring uninterrupted supply and regulatory confidence for our customers worldwide.
Bulk procurement of nicotinamide always raises important questions: what is the minimum you can order, and how long before the goods are packed and on the truck? We understand how planning hinges on these two points; year after year, our customers approach us seeking clarity and reliability for their purchasing programs. Our approach rests on transparency, responsiveness, and industry standards built from handling high-volume, GMP-compliant nicotinamide production.
From a manufacturing standpoint, MOQ is not just an administrative barrier—we set it to balance several factors: production efficiency, resource allocation, packaging, and logistics. For food, pharma, and feed applications, most clients initiate business with us at drum or pallet scale, sometimes running up to a full container. Our typical MOQ reflects the practical output of our processing and packing lines. Currently, the MOQ for nicotinamide stands at 500 kg. Below this, we risk equipment underload, increased costs, and logistics arrangements that erode efficiency for all involved. Orders at or above 500 kg allow us to schedule uninterrupted batch production, optimize quality checks, and ensure that loading times are predictable for both us and our logistics partners.
Lead times stem from raw material planning, batch production schedules, and final quality releases. Our process has several checkpoints: raw material validation, continuous production, filtration, drying, QC verification, packing, and final review before shipment. For standard bulk orders—500 kg and above—our regular lead time runs 10–15 working days after receipt of purchase order and specification agreement. Some customers require certificate of analysis, special particle size, or custom packaging. In these cases, we work with our QA and logistics teams to adjust the timeline transparently, flagging every step as we go.
Fluctuations in lead time sometimes arise from spikes in global demand, maintenance cycles, or port congestion. We invest in process automation and equipment redundancy to keep these interruptions to a minimum. Since our production runs are staggered throughout the month, pre-scheduled standing orders help smooth out delivery windows. Clients with annual contracts see fewer delays because we lock in their slot in our batch rotations. This helps everyone—our warehouse, transport teams, and the end user relying on a precise delivery schedule—to maintain predictability.
Meeting MOQ and lead time targets does not end with packing the last drum. Our responsibility includes verifying certificate authenticity, securing optimal packaging to guard against humidity, and arranging prompt pickup. There are times when we navigate unexpected surges—unusual weather, global health events, or last-minute spec changes—but we keep our customers informed well before their schedule would be impacted. This trust only builds through consistency and open communication.
We recognize that raw material procurement, formulation trials, and production scale-ups all depend on the basic facts of MOQ and lead time. Those two numbers allow downstream planning without guesswork. We keep those numbers as stable as the market allows, because our own operations and our customers’ plans depend on that reliability. There is no room for half-measures; you either keep pace with the market and your customer’s needs, or you lose the privilege to serve.
Our factory runs continuous production lines for nicotinamide, shipping hundreds of tons annually to various corners of the globe. Each lot never moves out the door without thorough safety checks and compliance audits. Global regulations stand at the front of every shipment plan. We navigate international, maritime, air, and local transport rules to keep our product moving safely and without delay.
On the production floor, we keep updated with both the UN Model Regulations and region-specific legislation, such as the US DOT, IATA for air, and IMDG Code for sea freight. Nicotinamide itself doesn’t fall under the hazardous materials governed for restricted or special handling by these systems. In our daily practice, that means bulk shipments—whether in fiber drums, paper sacks with liners, or FIBCs—face less regulatory friction compared to strictly classified hazardous goods. Our shipping documentation always reflects accurate chemical identification, correct labeling, and includes the latest safety data sheets. This keeps our shipments clear at customs and reduces unnecessary holdups.
Nicotinamide enters global commerce as a relatively low-risk chemical. At the manufacturing stage, we store and convey it in dry, well-ventilated conditions. We use dedicated process lines to avoid contamination. We train our warehouse and logistics teams rigorously, not because regulations say so, but because good practice demands it. Our standard packaging prevents exposure to air and moisture and withstands the rigors of international transport. Packaging integrity means fewer spills, less product loss, and worker safety—issues we measure by the absence of transit incidents and post-shipment complaints.
Our teams regularly review the alignment of transport operations with the latest updates from national and supranational authorities. This vigilance ensures every customer receives delivery without unexpected regulatory obstacles. Audits never turn up non-conformities in documentation or packaging, and we welcome surprise inspections. Over the years, we've found that proactive training, strong supplier communication, and engagement with trade associations help us stay ahead of any regulatory drift.
For all shipments, we attach batch-specific documentation and guarantee packaging materials comply with international food grade and pharmaceutical standards where applicable. In the rare event of accidental damage during transit, our internal protocols kick in quickly—a point of pride for our logistics team, which has minimized lost-time safety incidents year-over-year. By investing in clear labeling, up-to-date paperwork, and premium packaging material, we foster confidence between our operations and the customers’ inbound supply chain managers.
No regulation remains static. We monitor regulatory advisories and participate in working groups for chemical safety and transport best practices. Where issues emerge, our technical team speaks directly with authorities to clarify and, where possible, advocate for clear, practical interpretations that keep global supply chains agile without sacrificing safety. We adjust packaging, revise training, or upgrade shipping containers as soon as credible new concerns reach our attention.
By staying in step with industry standards and focusing every part of our operation on compliance and best practice, we ensure our nicotinamide reaches customers safely and reliably. Regulatory compliance is not a box-ticking exercise; it forms part of every production and shipping decision we make.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales7@bouling-chem.com, +8615371019725 or WhatsApp: +8615371019725
